394 related articles for article (PubMed ID: 22169682)
1. Randomized comparison of everolimus-eluting versus bare-metal stents in patients with critical limb ischemia and infrapopliteal arterial occlusive disease.
Bosiers M; Scheinert D; Peeters P; Torsello G; Zeller T; Deloose K; Schmidt A; Tessarek J; Vinck E; Schwartz LB
J Vasc Surg; 2012 Feb; 55(2):390-8. PubMed ID: 22169682
[TBL] [Abstract][Full Text] [Related]
2. Primary everolimus-eluting stenting versus balloon angioplasty with bailout bare metal stenting of long infrapopliteal lesions for treatment of critical limb ischemia.
Karnabatidis D; Spiliopoulos S; Diamantopoulos A; Katsanos K; Kagadis GC; Kakkos S; Siablis D
J Endovasc Ther; 2011 Feb; 18(1):1-12. PubMed ID: 21314342
[TBL] [Abstract][Full Text] [Related]
3. Everolimus-Eluting Stent for Patients With Critical Limb Ischemia and Infrapopliteal Arterial Occlusive Disease.
Giaquinta A; Vincenzo A; De Marco E; Veroux M; Veroux P
Vasc Endovascular Surg; 2017 Feb; 51(2):60-66. PubMed ID: 28100126
[TBL] [Abstract][Full Text] [Related]
4. Outcome of a drug-eluting stent in longer below-the-knee lesions in patients with critical limb ischemia.
Bosiers MJ; Deloose K; Peeters P; Torsello G; Zeller T; Scheinert D; Schmidt A; Maene L; Keirse K; Varcoe R; Bosiers M
J Cardiovasc Surg (Torino); 2017 Feb; 58(1):49-54. PubMed ID: 27455888
[TBL] [Abstract][Full Text] [Related]
5. Primary use of sirolimus-eluting stents in the infrapopliteal arteries.
Rastan A; Schwarzwälder U; Noory E; Taieb FH; Beschorner U; Sixt S; Bürgelin K; Amantea P; Neumann FJ; Zeller T
J Endovasc Ther; 2010 Aug; 17(4):480-7. PubMed ID: 20681763
[TBL] [Abstract][Full Text] [Related]
6. Real-World Performance of Paclitaxel Drug-Eluting Bare Metal Stenting (Zilver PTX) for the Treatment of Femoropopliteal Occlusive Disease.
Tran K; Ullery BW; Kret MR; Lee JT
Ann Vasc Surg; 2017 Jan; 38():90-98. PubMed ID: 27554688
[TBL] [Abstract][Full Text] [Related]
7. Sirolimus-eluting versus bare stents after suboptimal infrapopliteal angioplasty for critical limb ischemia: enduring 1-year angiographic and clinical benefit.
Siablis D; Karnabatidis D; Katsanos K; Kagadis GC; Kraniotis P; Diamantopoulos A; Tsolakis J
J Endovasc Ther; 2007 Apr; 14(2):241-50. PubMed ID: 17484536
[TBL] [Abstract][Full Text] [Related]
8. Sirolimus-eluting stents for the treatment of infrapopliteal arteries in chronic limb ischemia: long-term clinical and angiographic follow-up.
Werner M; Schmidt A; Freyer M; Bausback Y; Bräunlich S; Friedenberger J; Schuster J; Botsios S; Scheinert D; Ulrich M
J Endovasc Ther; 2012 Feb; 19(1):12-9. PubMed ID: 22313195
[TBL] [Abstract][Full Text] [Related]
9. First clinical trial of nitinol self-expanding everolimus-eluting stent implantation for peripheral arterial occlusive disease.
Lammer J; Bosiers M; Zeller T; Schillinger M; Boone E; Zaugg MJ; Verta P; Peng L; Gao X; Schwartz LB
J Vasc Surg; 2011 Aug; 54(2):394-401. PubMed ID: 21658885
[TBL] [Abstract][Full Text] [Related]
10. Use of drug-eluting stents in patients with critical limb ischemia and infrapopliteal arterial disease: a real-world single-center experience.
AbuRahma AF; Beasley M; Davis M; Adams E; Lee A; Shapiro J; Dean LS; Davis E
J Vasc Surg; 2021 Nov; 74(5):1619-1625. PubMed ID: 34182023
[TBL] [Abstract][Full Text] [Related]
11. One-Year Outcomes of the Paclitaxel-Eluting, Self-Expanding Stentys Stent System in the Treatment of Infrapopliteal Lesions in Patients With Critical Limb Ischemia.
Bosiers M; Callaert J; Keirse K; Hendriks JMH; Peeters P; Verbist J; Maene L; Beelen R; Deloose K
J Endovasc Ther; 2017 Jun; 24(3):311-316. PubMed ID: 28351310
[TBL] [Abstract][Full Text] [Related]
12. Long-Term Follow-up of the PADI Trial: Percutaneous Transluminal Angioplasty Versus Drug-Eluting Stents for Infrapopliteal Lesions in Critical Limb Ischemia.
Spreen MI; Martens JM; Knippenberg B; van Dijk LC; de Vries JPM; Vos JA; de Borst GJ; Vonken EPA; Bijlstra OD; Wever JJ; Statius van Eps RG; Mali WPTM; van Overhagen H
J Am Heart Assoc; 2017 Apr; 6(4):. PubMed ID: 28411244
[TBL] [Abstract][Full Text] [Related]
13. Impact of lesion length and vessel size on clinical outcomes after percutaneous coronary intervention with everolimus- versus paclitaxel-eluting stents pooled analysis from the SPIRIT (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System) and COMPARE (Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice) Randomized Trials.
Claessen BE; Smits PC; Kereiakes DJ; Parise H; Fahy M; Kedhi E; Serruys PW; Lansky AJ; Cristea E; Sudhir K; Sood P; Simonton CA; Stone GW
JACC Cardiovasc Interv; 2011 Nov; 4(11):1209-15. PubMed ID: 22115661
[TBL] [Abstract][Full Text] [Related]
14. Experience With the Absorb Everolimus-Eluting Bioresorbable Vascular Scaffold in Arteries Below the Knee: 12-Month Clinical and Imaging Outcomes.
Varcoe RL; Schouten O; Thomas SD; Lennox AF
JACC Cardiovasc Interv; 2016 Aug; 9(16):1721-8. PubMed ID: 27539693
[TBL] [Abstract][Full Text] [Related]
15. Commentary: infrapopliteal angioplasty with drug-eluting stents: from heart to toe.
Siablis D; Katsanos K; Karnabatidis D
J Endovasc Ther; 2010 Aug; 17(4):488-91. PubMed ID: 20681764
[No Abstract] [Full Text] [Related]
16. Update on PADI trial: percutaneous transluminal angioplasty and drug-eluting stents for infrapopliteal lesions in critical limb ischemia.
Martens JM; Knippenberg B; Vos JA; de Vries JP; Hansen BE; van Overhagen H;
J Vasc Surg; 2009 Sep; 50(3):687-9. PubMed ID: 19700099
[TBL] [Abstract][Full Text] [Related]
17. Sirolimus-eluting stents vs. bare-metal stents for treatment of focal lesions in infrapopliteal arteries: a double-blind, multi-centre, randomized clinical trial.
Rastan A; Tepe G; Krankenberg H; Zahorsky R; Beschorner U; Noory E; Sixt S; Schwarz T; Brechtel K; Böhme C; Neumann FJ; Zeller T
Eur Heart J; 2011 Sep; 32(18):2274-81. PubMed ID: 21622669
[TBL] [Abstract][Full Text] [Related]
18. 3-year clinical follow-up of the XIENCE V everolimus-eluting coronary stent system in the treatment of patients with de novo coronary artery lesions: the SPIRIT II trial (Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients with de novo Native Coronary Artery Lesions).
Garg S; Serruys P; Onuma Y; Dorange C; Veldhof S; Miquel-Hébert K; Sudhir K; Boland J; Huber K; Garcia E; te Riele JA;
JACC Cardiovasc Interv; 2009 Dec; 2(12):1190-8. PubMed ID: 20129545
[TBL] [Abstract][Full Text] [Related]
19. Paclitaxel-coated balloon angioplasty versus drug-eluting stenting for the treatment of infrapopliteal long-segment arterial occlusive disease: the IDEAS randomized controlled trial.
Siablis D; Kitrou PM; Spiliopoulos S; Katsanos K; Karnabatidis D
JACC Cardiovasc Interv; 2014 Sep; 7(9):1048-56. PubMed ID: 25234679
[TBL] [Abstract][Full Text] [Related]
20. Five-year long-term clinical follow-up of the XIENCE V everolimus eluting coronary stent system in the treatment of patients with de novo coronary artery lesions: the SPIRIT FIRST trial.
Wiemer M; Serruys PW; Miquel-Hebert K; Neumann FJ; Piek JJ; Grube E; Haase J; Thuesen L; Hamm C
Catheter Cardiovasc Interv; 2010 Jun; 75(7):997-1003. PubMed ID: 20517959
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
